Migraine Market
Growth information, by types (Episodic and Chronic), by treatment type
(Preventive and Abortive), by drug class (Triptans, Ergots, and Others) -
Global Forecast to 2022
Market Analysis
The global Migraine Market Growth is anticipated to grow at an
impressive CAGR between 2013-2022, states the latest Market Research Future
(MRFR) report. Migraine is basically a neurological condition which can result
in multiple symptoms. It is characterized by a debilitating, intense headache.
Often migraine runs in families and can affect every age group. Sensitivity to
sound and light, difficulty speaking, tingling or numbness, vomiting, and
nausea are common symptoms of migraines.
Migraine may begin
during childhood, or it may not occur until early adulthood. Generally, women
are more likely to suffer from migraines than men. Migraine with aura or
classic migraines and without aura or common migraine are the two common
categories of migraine. The pain mostly affects the area of the forehead, is
usually on one side of the head, yet may shift, or occur on both sides of the
head.
Numerous factors are
pushing the growth of the market such as growing awareness regarding the
prevention and also treatment of migraine, rising healthcare expenditure,
launch and FDA approval of new migraine drugs, rising cigarette consumption,
increasing intake of hormonal medications, lifestyle changes, rising disease
prevalence, and stressed lifestyle. Additional factors propelling the growth of
the Migraine Market Growth include
accelerating economic growth, rising prevalence of migraine, increasing female
population, demand for hormonal medications, high unmet needs, and launch of
calcitonin gene-related peptide (CGRP).
On the contrary,
different side effects from migraine drugs, stringent government regulations,
regulatory challenges, scarcity of proper diagnosis, rising preference of
alternative therapies, and increasing investment in drug R&D are factors
that may restrict the Migraine Market
Growth growth during the forecast period.
Market
Segmentation
The global Migraine
Market Growth has been segmented in
terms of drug class, types, and treatment types.
By types, the Migraine
Market Growth is segmented into chronic
as well as episodic. Of these, the episodic segment will lead the market during
the forecast period owing to its increasing prevalence.
By treatment types, the Migraine
Market Growth is segmented into abortive
and preventive. Of these, the abortive segment will dominate the market during
the forecast period for the ease of self-administration in those with migraines
accompanied by vomiting and nausea.
By drug class, the Migraine
Market Growth is segmented into ergots,
triptans, and others. Of these, triptans will have maximum share in the market
during the forecast period.
Regional Analysis
The global Migraine
Market Growth report is geographically
distributed across the following key regions: North America, Europe, the Asia
Pacific (APAC), and the Rest of the World (RoW). Among these, North America
will have the lion’s share in the market during the forecast period. Various
factors propelling the growth of the Migraine Market Growth in the region include the launch of
CGRP based therapies, adoption of novel therapeutics, huge target population,
especially in the US, increasing R&D activities in the region, and
increasing incidence of migraine. The US is the major contributor in the
region.
The Migraine Market Growth in the APAC region will have favorable
growth during the forecast period. Various factors propelling the growth of the
Migraine Market Growth in the region
include increasing healthcare expenditure, growing disease awareness, huge
underserved population, and low-cost production of drugs.
The Migraine Market Growth in Europe will have a notable growth
during the forecast period for rising stress levels, changing lifestyles, and
rising incidence of hormonal imbalance.
The Migraine Market Growth in the RoW will have stable growth
during the forecast period.
Key Players
Notable players profiled in the global Migraine
Market Growth report include Pfizer,
Inc., Eisai Inc., Impax Laboratories, Eli Lilly and Company, Abbott
Laboratories, Allegan, Luitpold Pharmaceuticals, Klaria, Johnson and Johnson,
Kowa Pharmaceuticals America, GlaxoSmithKline plc., OptiNose, Meda, AstraZeneca
plc, Merck, and others. Key players have used specific strategies to stay head
and shoulders above others in the competition, such as collaborations,
expansions, mergers and acquisitions, research and development activities, new
product launches, and more.
Industry News
October 2019: Eli
Lilly’s Reyvow has received FDA approval to treat acute migraines. It is the
only and foremost medicine that has received approval from the FDA to treat
acute migraines.
No comments:
Post a Comment